Synthesis, Inhibitory Activity of Cholinesterases, and Neuroprotective Profile of Novel 1,8-Naphthyridine Derivatives

被引:74
作者
de los Rios, Cristobal [1 ,2 ,4 ]
Egea, Javier [1 ]
Marco-Contelles, Jose [2 ]
Leon, Rafael [1 ]
Samadi, Abdelouahid [2 ]
Iriepa, Isabel [4 ]
Moraleda, Ignacio [4 ]
Galvez, Enrique [4 ]
Garcia, Antonio G. [1 ,3 ]
Lopez, Manuela G. [1 ]
Villarroya, Mercedes [1 ]
Romero, Alejandro [1 ]
机构
[1] Univ Autonoma Madrid, Fac Med, Dept Farmacol & Terapeut, Inst Teofilo Hernando, E-28029 Madrid, Spain
[2] CSIC, Inst Quim Organ Gen, Lab Rad Libres & Quim Computac, E-28006 Madrid, Spain
[3] Hosp Univ Princesa, Serv Farmacol Clin, Madrid 28006, Spain
[4] Univ Alcala de Henares, Dept Quim Organ, Fac Farm, Alcala De Henares 28817, Spain
关键词
TACRINE-DIHYDROPYRIDINE HYBRIDS; ALZHEIMERS-DISEASE; ACETYLCHOLINESTERASE INHIBITORS; NEUROBLASTOMA-CELLS; HIPPOCAMPAL SLICES; HUMAN-ERYTHROCYTE; OXIDATIVE STRESS; DIRECTED LIGANDS; PERIPHERAL SITE; GALANTAMINE;
D O I
10.1021/jm901902w
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
1,8-Naphthyridine derivatives related to 17 (ITH4012), a neuroprotective compound reported by our research group, have been synthesized. In general, they have shown better inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) than most tacrine derivatives previously synthesized in our laboratory. The compounds presented an interesting neuroprotective profile in SH-SY5Y neuroblastoma cells stressed with rotenone/oligomycin A. Moreover, compound 14 (ethyl 5-amino-2-methy1-6,7,8,9-tetrahydrobenzo[b][1,8]naphthyridine-3-carboxylate) also caused protection in cells stressed with okadaic acid (OA) or amyloid beta 1-42 peptide (A beta(1-42)). Interestingly, compound 14 prevented the OA-induced PP2A inhibition, one of the enzymes implicated in tau dephosphorylation. This compound also exhibited neuroprotection against neurotoxicity elicited by oxygen and glucose deprivation in hippocampal slices. Because these stressors caused neuronal damage related to physiopathological hallmarks found in the brain of Alzheimer's disease (AD) patients, we conclude that compound 14 deserves further in vivo studies in AD models to test its therapeutic potential in this disease.
引用
收藏
页码:5129 / 5143
页数:15
相关论文
共 75 条
  • [1] ABUSHANAB FA, 1995, SYNTHESIS-STUTTGART, P923
  • [2] ANATOMY OF ACETYLCHOLINESTERASE CATALYSIS - REACTION DYNAMICS ANALOGY FOR HUMAN ERYTHROCYTE AND ELECTRIC-EEL ENZYMES
    ACHESON, SA
    QUINN, DM
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1040 (02) : 199 - 205
  • [3] INHIBITION OF ACETYLCHOLINESTERASE FROM DIFFERENT SPECIES BY ORGANOPHOSPHORUS COMPOUNDS, CARBAMATES AND METHYLSULFONYLFLUORIDE
    ANDERSEN, RA
    AARAAS, I
    GAARE, G
    FONNUM, F
    [J]. GENERAL PHARMACOLOGY, 1977, 8 (5-6): : 331 - 334
  • [4] The use of okadaic acid in vivo and the induction of molecular changes typical for Alzheimer's disease
    Arendt, T
    Holzer, M
    Brückner, MK
    Janke, C
    Gärtner, U
    [J]. NEUROSCIENCE, 1998, 85 (04) : 1337 - 1340
  • [5] Galantamine prevents apoptosis induced by β-amyloid and thapsigargin:: involvement of nicotinic acetylcholine receptors
    Arias, E
    Alés, E
    Gabilan, NH
    Cano-Abad, MF
    Villarroya, M
    García, AG
    López, MG
    [J]. NEUROPHARMACOLOGY, 2004, 46 (01) : 103 - 114
  • [6] Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells:: Role of nicotinic receptors
    Arias, E
    Gallego-Sandín, S
    Villarroya, M
    García, AG
    López, MG
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) : 1346 - 1353
  • [7] ATACK JR, 1989, J PHARMACOL EXP THER, V249, P194
  • [8] Mitochondria as a target for neurotoxins and neuroprotective agents
    Bachurin, SO
    Shevtsova, EP
    Kireeva, EG
    Oxenkrug, GF
    Sablin, SO
    [J]. NEUROPROTECTIVE AGENTS, 2003, 993 : 334 - 344
  • [9] β-amyloid aggregation induced by human acetylcholinesterase:: inhibition studies
    Bartolini, M
    Bertucci, C
    Cavrini, V
    Andrisano, V
    [J]. BIOCHEMICAL PHARMACOLOGY, 2003, 65 (03) : 407 - 416
  • [10] cAMP counter-regulates insulin-mediated protein phosphatase-2A inactivation in rat skeletal muscle cells
    Begum, N
    Ragolia, L
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (49) : 31166 - 31171